Speak with one of our advisors: 0800 085 6696 or
 

Test expected to become important tool in fight against prostate cancer and prevention of unnecessary biopsies

November 2013: OPKO Health, Inc. commences a pivotal, multi-center clinical validation study for the company’s proprietary 4Kscore™ test for the prediction of prostate cancer prior to prostate biopsy. The 4Kscore™ test is based on over a decade of research of a four kallikrein panel of biomarkers conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. It is believed that the test will address a significant need for better tests to identify men at risk for aggressive prostate cancer, while at the same time avoiding unnecessary, costly, and potentially harmful treatments.

Read More
PSACheck
If you want fast, accurate screening for prostate cancer
ProstateGene
If you are worried about prostate cancer due to your father or grand father being diagnosed with it click the icon above
© 2019 ProstateHealth UK, 1 The Mill, Copley Hill Business Park, Cambridge Road, Cambridge CB22 3GN - Registered in England and Wales. Company registration number 08866941
All data send on this website is encrypted (SSL).